Postmenopausal endometrial hyperplasia: role of danazol therapy

L. Mariani, A. Sedati, R. Giovinazzi, R. Sindico, G. Atlante

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVES: To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously. METHODS: Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months. RESULTS: After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63). CONCLUSIONS: Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalInternational Journal of Gynecology and Obstetrics
Volume44
Issue number2
DOIs
Publication statusPublished - 1994

Fingerprint

Danazol
Endometrial Hyperplasia
Uterine Hemorrhage
Hyperplasia
Withholding Treatment
Progestins
Therapeutics
Endometrium

Keywords

  • Danazol
  • Endometrial hyperplasia

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Postmenopausal endometrial hyperplasia : role of danazol therapy. / Mariani, L.; Sedati, A.; Giovinazzi, R.; Sindico, R.; Atlante, G.

In: International Journal of Gynecology and Obstetrics, Vol. 44, No. 2, 1994, p. 155-159.

Research output: Contribution to journalArticle

Mariani, L. ; Sedati, A. ; Giovinazzi, R. ; Sindico, R. ; Atlante, G. / Postmenopausal endometrial hyperplasia : role of danazol therapy. In: International Journal of Gynecology and Obstetrics. 1994 ; Vol. 44, No. 2. pp. 155-159.
@article{419b7cad304f4573ba91ffe3db137887,
title = "Postmenopausal endometrial hyperplasia: role of danazol therapy",
abstract = "OBJECTIVES: To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously. METHODS: Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months. RESULTS: After cessation of treatment, 82.8{\%} of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8{\%}), secretory (11.9{\%}) or proliferative (4.2{\%}) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90{\%} of the responders (59/63). CONCLUSIONS: Although 17.1{\%} of the women had a persistence of the hyperplasia and 8.4{\%} of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.",
keywords = "Danazol, Endometrial hyperplasia",
author = "L. Mariani and A. Sedati and R. Giovinazzi and R. Sindico and G. Atlante",
year = "1994",
doi = "10.1016/0020-7292(94)90071-X",
language = "English",
volume = "44",
pages = "155--159",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Postmenopausal endometrial hyperplasia

T2 - role of danazol therapy

AU - Mariani, L.

AU - Sedati, A.

AU - Giovinazzi, R.

AU - Sindico, R.

AU - Atlante, G.

PY - 1994

Y1 - 1994

N2 - OBJECTIVES: To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously. METHODS: Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months. RESULTS: After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63). CONCLUSIONS: Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.

AB - OBJECTIVES: To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously. METHODS: Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months. RESULTS: After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63). CONCLUSIONS: Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.

KW - Danazol

KW - Endometrial hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=0028120672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028120672&partnerID=8YFLogxK

U2 - 10.1016/0020-7292(94)90071-X

DO - 10.1016/0020-7292(94)90071-X

M3 - Article

C2 - 7911101

AN - SCOPUS:0028120672

VL - 44

SP - 155

EP - 159

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 2

ER -